CALCIUM GLUTAMATE ANHYDROUS

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H7NO4.Ca
Molecular Weight	185.191
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CALCIUM GLUTAMATE ANHYDROUS

Structure Search

SMILES

[Ca++].N[C@@H](CCC([O-])=O)C([O-])=O

InChI

InChIKey=NIDRASOKXCQPKX-DFWYDOINSA-L

InChI=1S/C5H9NO4.Ca/c6-3(5(9)10)1-2-4(7)8;/h3H,1-2,6H2,(H,7,8)(H,9,10);/q;+2/p-2/t3-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C5H7NO4
Molecular Weight	145.1134
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Hypocalcemia 73 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 511	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 175 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 438	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 438	Unknown Approved Use Unknown
Unknown 2596
Hypocalcemia 73 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8583	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Studies on the calcemic effect of intravenous secretin in humans.	1975 Jun	1220513
Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes.	2000 Dec	11204457
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.	2000 Dec	11093801
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade.	2000 Dec 15	11124974
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.	2000 Nov	11089548
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.	2000 Nov	11071371
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.	2000 Nov 10	11073891
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.	2001 Apr	11245615
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.	2001 Apr 27	11278295
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.	2001 Apr 7	11298490
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.	2001 Aug	11572466
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.	2001 Aug 28	11513607
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.	2001 Dec 21	11592964
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Molecular and functional characterization of a family of rat brain T-type calcium channels.	2001 Feb 9	11073957
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.	2001 Jul	11435619
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.	2001 Jul	11435522
Analysis of the native quaternary structure of vanilloid receptor 1.	2001 Jul 27	11358970
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.	2001 Jun	11425647
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D.	2001 Jun	11356622
[Acute renal failure caused by hypercalcemia].	2001 Jun 10	11464680
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Cloning and characterization of a novel human histamine receptor.	2001 Mar	11181941
Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines.	2001 Mar	11181528
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.	2001 Mar 15	11238657
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.	2001 Mar 2	11230109
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses.	2001 Mar 27	11297424
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.	2001 Nov 1	11705452
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.	2001 Nov 30	11577072
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.	2001 Oct	11606325
Familial intrahepatic cholestasis 1: studies of localization and function.	2001 Oct	11584374
Microarray analysis of differential gene expression in lead-exposed astrocytes.	2001 Oct 1	11578147
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.	2001 Oct 12	11597992
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.	2001 Sep	11500311
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.	2001 Sep 1	11533133
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.	2001 Sep 15	11535132
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.	2001 Sep 7	11553362
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.	2002 Jul	12101159
Expression of functional CCR and CXCR chemokine receptors in podocytes.	2002 Jun 15	12055238
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.	2002 Sep	12181424
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate].	2006 Oct	17012812
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity.	2009 Jul-Aug	19567386
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans.	2012 Apr	22019281
Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.	2014 Jan 17	24438153
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.	2014 Jul	24705069
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.	2015 Sep 16	26376110

Patents

Sample Use Guides

In Vivo Use Guide

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:53:07 GMT 2025` Edited by `admin` on `Mon Mar 31 19:53:07 GMT 2025`
Record UNII	59U29NCD0V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM L-GLUTAMATE (1:1)

Preferred Name

English

CALCIUM GLUTAMATE ANHYDROUS

Common Name

English

MONOCALCIUM GLUTAMATE

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

241-223-5